The global Bispecific Antibody Molecular Drug market was valued at US$ 500 million in 2023 and is anticipated to reach US$ 802.9 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.

Bispecific Antibody Molecular Drug Market

Bispecific antibody molecular drugs are developed on the basis of monoclonal antibodies and are regarded as the second-generation antibody therapy for tumor treatment. Bispecific antibody molecules do not exist in the natural state and can only be prepared artificially. Its development is through the co-expression of two different H chains and two different L chains. Therefore, bispecific antibodies can specifically bind 2 different antigens.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Bispecific Antibody Molecular Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific Antibody Molecular Drug.

Report Scope

The Bispecific Antibody Molecular Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bispecific Antibody Molecular Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bispecific Antibody Molecular Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Bispecific Antibody Molecular Drug Market Report

Report Metric	Details
Report Name	Bispecific Antibody Molecular Drug Market
Accounted market size in 2023	US$ 500 million
Forecasted market size in 2030	US$ 802.9 million
CAGR	7.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	EGFR×HER3 Target PD-1×CTLA-4 Target HER2×HER3 Target
Segment by Application	Pancreatic Cancer Breast Cancer Colorectal Cancer Non-Small Cell Lung Cancer Solid Tumor Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	MacroGenics, Xencor, Medimmune, Merrimsck, Merus NV, Genentech, Zhongshan Kangfang Biology Medicine, Sichuan Baili Pharmaceutical, Alphamab Oncology, Amgen
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bispecific Antibody Molecular Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bispecific Antibody Molecular Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Bispecific Antibody Molecular Drug Market growing?

Ans: The Bispecific Antibody Molecular Drug Market witnessing a CAGR of 7.0% during the forecast period 2024-2030.

What is the Bispecific Antibody Molecular Drug Market size in 2030?

Ans: The Bispecific Antibody Molecular Drug Market size in 2030 will be US$ 802.9 million.

Who are the main players in the Bispecific Antibody Molecular Drug Market report?

Ans: The main players in the Bispecific Antibody Molecular Drug Market are MacroGenics, Xencor, Medimmune, Merrimsck, Merus NV, Genentech, Zhongshan Kangfang Biology Medicine, Sichuan Baili Pharmaceutical, Alphamab Oncology, Amgen

What are the Application segmentation covered in the Bispecific Antibody Molecular Drug Market report?

Ans: The Applications covered in the Bispecific Antibody Molecular Drug Market report are Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Others

What are the Type segmentation covered in the Bispecific Antibody Molecular Drug Market report?

Ans: The Types covered in the Bispecific Antibody Molecular Drug Market report are EGFR×HER3 Target, PD-1×CTLA-4 Target, HER2×HER3 Target

1 Bispecific Antibody Molecular Drug Market Overview

1.1 Product Overview and Scope of Bispecific Antibody Molecular Drug

1.2 Bispecific Antibody Molecular Drug Segment by Type

1.2.1 Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2024-2030)

1.2.2 EGFR×HER3 Target

1.2.3 PD-1×CTLA-4 Target

1.2.4 HER2×HER3 Target

1.3 Bispecific Antibody Molecular Drug Segment by Application

1.3.1 Global Bispecific Antibody Molecular Drug Market Value by Application: (2024-2030)

1.3.2 Pancreatic Cancer

1.3.3 Breast Cancer

1.3.4 Colorectal Cancer

1.3.5 Non-Small Cell Lung Cancer

1.3.6 Solid Tumor

1.3.7 Others

1.4 Global Bispecific Antibody Molecular Drug Market Size Estimates and Forecasts

1.4.1 Global Bispecific Antibody Molecular Drug Revenue 2019-2030

1.4.2 Global Bispecific Antibody Molecular Drug Sales 2019-2030

1.4.3 Global Bispecific Antibody Molecular Drug Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Bispecific Antibody Molecular Drug Market Competition by Manufacturers

2.1 Global Bispecific Antibody Molecular Drug Sales Market Share by Manufacturers (2019-2024)

2.2 Global Bispecific Antibody Molecular Drug Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Bispecific Antibody Molecular Drug Average Price by Manufacturers (2019-2024)

2.4 Global Bispecific Antibody Molecular Drug Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Type & Application

2.7 Bispecific Antibody Molecular Drug Market Competitive Situation and Trends

2.7.1 Bispecific Antibody Molecular Drug Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Bispecific Antibody Molecular Drug Players Market Share by Revenue

2.7.3 Global Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Bispecific Antibody Molecular Drug Retrospective Market Scenario by Region

3.1 Global Bispecific Antibody Molecular Drug Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Bispecific Antibody Molecular Drug Global Bispecific Antibody Molecular Drug Sales by Region: 2019-2030

3.2.1 Global Bispecific Antibody Molecular Drug Sales by Region: 2019-2024

3.2.2 Global Bispecific Antibody Molecular Drug Sales by Region: 2025-2030

3.3 Global Bispecific Antibody Molecular Drug Global Bispecific Antibody Molecular Drug Revenue by Region: 2019-2030

3.3.1 Global Bispecific Antibody Molecular Drug Revenue by Region: 2019-2024

3.3.2 Global Bispecific Antibody Molecular Drug Revenue by Region: 2025-2030

3.4 North America Bispecific Antibody Molecular Drug Market Facts & Figures by Country

3.4.1 North America Bispecific Antibody Molecular Drug Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Bispecific Antibody Molecular Drug Sales by Country (2019-2030)

3.4.3 North America Bispecific Antibody Molecular Drug Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Bispecific Antibody Molecular Drug Market Facts & Figures by Country

3.5.1 Europe Bispecific Antibody Molecular Drug Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Bispecific Antibody Molecular Drug Sales by Country (2019-2030)

3.5.3 Europe Bispecific Antibody Molecular Drug Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Bispecific Antibody Molecular Drug Market Facts & Figures by Country

3.6.1 Asia Pacific Bispecific Antibody Molecular Drug Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Bispecific Antibody Molecular Drug Sales by Country (2019-2030)

3.6.3 Asia Pacific Bispecific Antibody Molecular Drug Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Bispecific Antibody Molecular Drug Market Facts & Figures by Country

3.7.1 Latin America Bispecific Antibody Molecular Drug Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Bispecific Antibody Molecular Drug Sales by Country (2019-2030)

3.7.3 Latin America Bispecific Antibody Molecular Drug Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Bispecific Antibody Molecular Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Bispecific Antibody Molecular Drug Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Bispecific Antibody Molecular Drug Sales by Country (2019-2030)

3.8.3 Middle East and Africa Bispecific Antibody Molecular Drug Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Bispecific Antibody Molecular Drug Sales by Type (2019-2030)

4.1.1 Global Bispecific Antibody Molecular Drug Sales by Type (2019-2024)

4.1.2 Global Bispecific Antibody Molecular Drug Sales by Type (2025-2030)

4.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2019-2030)

4.2 Global Bispecific Antibody Molecular Drug Revenue by Type (2019-2030)

4.2.1 Global Bispecific Antibody Molecular Drug Revenue by Type (2019-2024)

4.2.2 Global Bispecific Antibody Molecular Drug Revenue by Type (2025-2030)

4.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2019-2030)

4.3 Global Bispecific Antibody Molecular Drug Price by Type (2019-2030)

5 Segment by Application

5.1 Global Bispecific Antibody Molecular Drug Sales by Application (2019-2030)

5.1.1 Global Bispecific Antibody Molecular Drug Sales by Application (2019-2024)

5.1.2 Global Bispecific Antibody Molecular Drug Sales by Application (2025-2030)

5.1.3 Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2019-2030)

5.2 Global Bispecific Antibody Molecular Drug Revenue by Application (2019-2030)

5.2.1 Global Bispecific Antibody Molecular Drug Revenue by Application (2019-2024)

5.2.2 Global Bispecific Antibody Molecular Drug Revenue by Application (2025-2030)

5.2.3 Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2019-2030)

5.3 Global Bispecific Antibody Molecular Drug Price by Application (2019-2030)

6 Key Companies Profiled

6.1 MacroGenics

6.1.1 MacroGenics Corporation Information

6.1.2 MacroGenics Description and Business Overview

6.1.3 MacroGenics Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.1.4 MacroGenics Bispecific Antibody Molecular Drug Product Portfolio

6.1.5 MacroGenics Recent Developments/Updates

6.2 Xencor

6.2.1 Xencor Corporation Information

6.2.2 Xencor Description and Business Overview

6.2.3 Xencor Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Xencor Bispecific Antibody Molecular Drug Product Portfolio

6.2.5 Xencor Recent Developments/Updates

6.3 Medimmune

6.3.1 Medimmune Corporation Information

6.3.2 Medimmune Description and Business Overview

6.3.3 Medimmune Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Medimmune Bispecific Antibody Molecular Drug Product Portfolio

6.3.5 Medimmune Recent Developments/Updates

6.4 Merrimsck

6.4.1 Merrimsck Corporation Information

6.4.2 Merrimsck Description and Business Overview

6.4.3 Merrimsck Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Merrimsck Bispecific Antibody Molecular Drug Product Portfolio

6.4.5 Merrimsck Recent Developments/Updates

6.5 Merus NV

6.5.1 Merus NV Corporation Information

6.5.2 Merus NV Description and Business Overview

6.5.3 Merus NV Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Merus NV Bispecific Antibody Molecular Drug Product Portfolio

6.5.5 Merus NV Recent Developments/Updates

6.6 Genentech

6.6.1 Genentech Corporation Information

6.6.2 Genentech Description and Business Overview

6.6.3 Genentech Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Genentech Bispecific Antibody Molecular Drug Product Portfolio

6.6.5 Genentech Recent Developments/Updates

6.7 Zhongshan Kangfang Biology Medicine

6.6.1 Zhongshan Kangfang Biology Medicine Corporation Information

6.6.2 Zhongshan Kangfang Biology Medicine Description and Business Overview

6.6.3 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolio

6.7.5 Zhongshan Kangfang Biology Medicine Recent Developments/Updates

6.8 Sichuan Baili Pharmaceutical

6.8.1 Sichuan Baili Pharmaceutical Corporation Information

6.8.2 Sichuan Baili Pharmaceutical Description and Business Overview

6.8.3 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolio

6.8.5 Sichuan Baili Pharmaceutical Recent Developments/Updates

6.9 Alphamab Oncology

6.9.1 Alphamab Oncology Corporation Information

6.9.2 Alphamab Oncology Description and Business Overview

6.9.3 Alphamab Oncology Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolio

6.9.5 Alphamab Oncology Recent Developments/Updates

6.10 Amgen

6.10.1 Amgen Corporation Information

6.10.2 Amgen Description and Business Overview

6.10.3 Amgen Bispecific Antibody Molecular Drug Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Amgen Bispecific Antibody Molecular Drug Product Portfolio

6.10.5 Amgen Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Bispecific Antibody Molecular Drug Industry Chain Analysis

7.2 Bispecific Antibody Molecular Drug Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Bispecific Antibody Molecular Drug Production Mode & Process

7.4 Bispecific Antibody Molecular Drug Sales and Marketing

7.4.1 Bispecific Antibody Molecular Drug Sales Channels

7.4.2 Bispecific Antibody Molecular Drug Distributors

7.5 Bispecific Antibody Molecular Drug Customers

8 Bispecific Antibody Molecular Drug Market Dynamics

8.1 Bispecific Antibody Molecular Drug Industry Trends

8.2 Bispecific Antibody Molecular Drug Market Drivers

8.3 Bispecific Antibody Molecular Drug Market Challenges

8.4 Bispecific Antibody Molecular Drug Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

MedImmune

Merus NV

Sichuan Baili Pharmaceutical

ALPHAMAB ONCOLOGY

Merrimsck

Zhongshan Kangfang Biology Medicine

List of Tables

Table 1. Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Bispecific Antibody Molecular Drug Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Bispecific Antibody Molecular Drug Market Competitive Situation by Manufacturers in 2023

Table 4. Global Bispecific Antibody Molecular Drug Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Bispecific Antibody Molecular Drug Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Bispecific Antibody Molecular Drug Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Bispecific Antibody Molecular Drug Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Bispecific Antibody Molecular Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Product Type & Application

Table 12. Global Key Manufacturers of Bispecific Antibody Molecular Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Bispecific Antibody Molecular Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bispecific Antibody Molecular Drug as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Bispecific Antibody Molecular Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Bispecific Antibody Molecular Drug Sales by Region (2019-2024) & (K Units)

Table 18. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2019-2024)

Table 19. Global Bispecific Antibody Molecular Drug Sales by Region (2025-2030) & (K Units)

Table 20. Global Bispecific Antibody Molecular Drug Sales Market Share by Region (2025-2030)

Table 21. Global Bispecific Antibody Molecular Drug Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2019-2024)

Table 23. Global Bispecific Antibody Molecular Drug Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Bispecific Antibody Molecular Drug Revenue Market Share by Region (2025-2030)

Table 25. North America Bispecific Antibody Molecular Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Bispecific Antibody Molecular Drug Sales by Country (2019-2024) & (K Units)

Table 27. North America Bispecific Antibody Molecular Drug Sales by Country (2025-2030) & (K Units)

Table 28. North America Bispecific Antibody Molecular Drug Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Bispecific Antibody Molecular Drug Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Bispecific Antibody Molecular Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Bispecific Antibody Molecular Drug Sales by Country (2019-2024) & (K Units)

Table 32. Europe Bispecific Antibody Molecular Drug Sales by Country (2025-2030) & (K Units)

Table 33. Europe Bispecific Antibody Molecular Drug Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Bispecific Antibody Molecular Drug Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Bispecific Antibody Molecular Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Bispecific Antibody Molecular Drug Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Bispecific Antibody Molecular Drug Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Bispecific Antibody Molecular Drug Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Bispecific Antibody Molecular Drug Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Bispecific Antibody Molecular Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Bispecific Antibody Molecular Drug Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Bispecific Antibody Molecular Drug Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Bispecific Antibody Molecular Drug Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Bispecific Antibody Molecular Drug Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Bispecific Antibody Molecular Drug Sales (K Units) by Type (2019-2024)

Table 51. Global Bispecific Antibody Molecular Drug Sales (K Units) by Type (2025-2030)

Table 52. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2019-2024)

Table 53. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2025-2030)

Table 54. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2019-2024)

Table 57. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2025-2030)

Table 58. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Type (2019-2024)

Table 59. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Type (2025-2030)

Table 60. Global Bispecific Antibody Molecular Drug Sales (K Units) by Application (2019-2024)

Table 61. Global Bispecific Antibody Molecular Drug Sales (K Units) by Application (2025-2030)

Table 62. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2019-2024)

Table 63. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2025-2030)

Table 64. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Bispecific Antibody Molecular Drug Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2019-2024)

Table 67. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2025-2030)

Table 68. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Application (2019-2024)

Table 69. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Application (2025-2030)

Table 70. MacroGenics Corporation Information

Table 71. MacroGenics Description and Business Overview

Table 72. MacroGenics Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. MacroGenics Bispecific Antibody Molecular Drug Product

Table 74. MacroGenics Recent Developments/Updates

Table 75. Xencor Corporation Information

Table 76. Xencor Description and Business Overview

Table 77. Xencor Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Xencor Bispecific Antibody Molecular Drug Product

Table 79. Xencor Recent Developments/Updates

Table 80. Medimmune Corporation Information

Table 81. Medimmune Description and Business Overview

Table 82. Medimmune Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Medimmune Bispecific Antibody Molecular Drug Product

Table 84. Medimmune Recent Developments/Updates

Table 85. Merrimsck Corporation Information

Table 86. Merrimsck Description and Business Overview

Table 87. Merrimsck Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Merrimsck Bispecific Antibody Molecular Drug Product

Table 89. Merrimsck Recent Developments/Updates

Table 90. Merus NV Corporation Information

Table 91. Merus NV Description and Business Overview

Table 92. Merus NV Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Merus NV Bispecific Antibody Molecular Drug Product

Table 94. Merus NV Recent Developments/Updates

Table 95. Genentech Corporation Information

Table 96. Genentech Description and Business Overview

Table 97. Genentech Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Genentech Bispecific Antibody Molecular Drug Product

Table 99. Genentech Recent Developments/Updates

Table 100. Zhongshan Kangfang Biology Medicine Corporation Information

Table 101. Zhongshan Kangfang Biology Medicine Description and Business Overview

Table 102. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product

Table 104. Zhongshan Kangfang Biology Medicine Recent Developments/Updates

Table 105. Sichuan Baili Pharmaceutical Corporation Information

Table 106. Sichuan Baili Pharmaceutical Description and Business Overview

Table 107. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product

Table 109. Sichuan Baili Pharmaceutical Recent Developments/Updates

Table 110. Alphamab Oncology Corporation Information

Table 111. Alphamab Oncology Description and Business Overview

Table 112. Alphamab Oncology Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Alphamab Oncology Bispecific Antibody Molecular Drug Product

Table 114. Alphamab Oncology Recent Developments/Updates

Table 115. Amgen Corporation Information

Table 116. Amgen Description and Business Overview

Table 117. Amgen Bispecific Antibody Molecular Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Amgen Bispecific Antibody Molecular Drug Product

Table 119. Amgen Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Bispecific Antibody Molecular Drug Distributors List

Table 123. Bispecific Antibody Molecular Drug Customers List

Table 124. Bispecific Antibody Molecular Drug Market Trends

Table 125. Bispecific Antibody Molecular Drug Market Drivers

Table 126. Bispecific Antibody Molecular Drug Market Challenges

Table 127. Bispecific Antibody Molecular Drug Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Bispecific Antibody Molecular Drug

Figure 2. Global Bispecific Antibody Molecular Drug Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Bispecific Antibody Molecular Drug Market Share by Type in 2023 & 2030

Figure 4. EGFR×HER3 Target Product Picture

Figure 5. PD-1×CTLA-4 Target Product Picture

Figure 6. HER2×HER3 Target Product Picture

Figure 7. Global Bispecific Antibody Molecular Drug Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Bispecific Antibody Molecular Drug Market Share by Application in 2023 & 2030

Figure 9. Pancreatic Cancer

Figure 10. Breast Cancer

Figure 11. Colorectal Cancer

Figure 12. Non-Small Cell Lung Cancer

Figure 13. Solid Tumor

Figure 14. Others

Figure 15. Global Bispecific Antibody Molecular Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Bispecific Antibody Molecular Drug Market Size (2019-2030) & (US$ Million)

Figure 17. Global Bispecific Antibody Molecular Drug Sales (2019-2030) & (K Units)

Figure 18. Global Bispecific Antibody Molecular Drug Average Price (US$/Unit) & (2019-2030)

Figure 19. Bispecific Antibody Molecular Drug Report Years Considered

Figure 20. Bispecific Antibody Molecular Drug Sales Share by Manufacturers in 2023

Figure 21. Global Bispecific Antibody Molecular Drug Revenue Share by Manufacturers in 2023

Figure 22. The Global 5 and 10 Largest Bispecific Antibody Molecular Drug Players: Market Share by Revenue in 2023

Figure 23. Bispecific Antibody Molecular Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 24. Global Bispecific Antibody Molecular Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 25. North America Bispecific Antibody Molecular Drug Sales Market Share by Country (2019-2030)

Figure 26. North America Bispecific Antibody Molecular Drug Revenue Market Share by Country (2019-2030)

Figure 27. United States Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Canada Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Europe Bispecific Antibody Molecular Drug Sales Market Share by Country (2019-2030)

Figure 30. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Country (2019-2030)

Figure 31. Germany Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. France Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. U.K. Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Italy Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Russia Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Asia Pacific Bispecific Antibody Molecular Drug Sales Market Share by Region (2019-2030)

Figure 37. Asia Pacific Bispecific Antibody Molecular Drug Revenue Market Share by Region (2019-2030)

Figure 38. China Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Japan Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. South Korea Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. India Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Australia Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. China Taiwan Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Bispecific Antibody Molecular Drug Sales Market Share by Country (2019-2030)

Figure 46. Latin America Bispecific Antibody Molecular Drug Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. UAE Bispecific Antibody Molecular Drug Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Bispecific Antibody Molecular Drug by Type (2019-2030)

Figure 56. Global Revenue Market Share of Bispecific Antibody Molecular Drug by Type (2019-2030)

Figure 57. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Type (2019-2030)

Figure 58. Global Sales Market Share of Bispecific Antibody Molecular Drug by Application (2019-2030)

Figure 59. Global Revenue Market Share of Bispecific Antibody Molecular Drug by Application (2019-2030)

Figure 60. Global Bispecific Antibody Molecular Drug Price (US$/Unit) by Application (2019-2030)

Figure 61. Bispecific Antibody Molecular Drug Value Chain

Figure 62. Bispecific Antibody Molecular Drug Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions